Dr. Andrew Cheng joined Akero in September, 2018, as President and Chief Executive Officer. Prior to joining Akero, Andrew served Gilead Sciences’ Senior Vice President from 2009-2015, then became Executive Vice President and Chief Medical Officer, during which time, he was responsible for the clinical development for the HIV program resulting in 11 FDA/EMA approved products. His past responsibilities also included medical affairs and the creation of the development operations department (regulatory affairs, clinical operations, pharmacovigilance, project management, clinical pharmacology, and biometrics), which covered clinical development support in multiple therapeutic areas including oncology, inflammation, respiratory, cardiovascular, HIV, and liver diseases.
Andrew previously served on the board of directors of Syntimmune, Inc., which was acquired by Alexion, and in August 2019, joined the board of directors of Arbutus Biopharma Corporation. He holds a BA in biology from Johns Hopkins University, and an MD and PhD in cellular and molecular biology from Columbia University College of Physicians and Surgeons. He completed his internal medicine residency at UCLA, and was board certified in internal medicine.
What is Andrew Cheng's net worth?
The estimated net worth of Andrew Cheng is at least $18.79 million as of November 1st, 2024. Dr. Cheng owns 605,417 shares of Akero Therapeutics stock worth more than $18,786,090 as of November 20th. This net worth estimate does not reflect any other investments that Dr. Cheng may own. Additionally, Dr. Cheng receives an annual salary of $1,040,000.00 as CEO at Akero Therapeutics. Learn More about Andrew Cheng's net worth.
What is Andrew Cheng's salary?
How do I contact Andrew Cheng?
Has Andrew Cheng been buying or selling shares of Akero Therapeutics?
Within the last three months, Andrew Cheng has sold $6,220,088.73 in shares of Akero Therapeutics stock. Most recently, Andrew Cheng sold 108,366 shares of the business's stock in a transaction on Friday, November 1st. The shares were sold at an average price of $31.73, for a transaction totalling $3,438,453.18. Following the completion of the sale, the chief executive officer now directly owns 605,417 shares of the company's stock, valued at $19,209,881.41. Learn More on Andrew Cheng's trading history.
Who are Akero Therapeutics' active insiders?
Are insiders buying or selling shares of Akero Therapeutics?
During the last twelve months, Akero Therapeutics insiders bought shares 2 times. They purchased a total of 150,000 shares worth more than $2,828,000.00. During the last twelve months, insiders at the sold shares 41 times. They sold a total of 777,704 shares worth more than $22,728,155.84. The most recent insider tranaction occured on November, 15th when insider Catriona Yale sold 9,061 shares worth more than $251,261.53. Insiders at Akero Therapeutics own 7.9% of the company.
Learn More about insider trades at Akero Therapeutics. Information on this page was last updated on 11/15/2024.
